A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform Through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers

A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform Through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06231953

Enrollment

4000

Registered

2024-01-30

Start date

2022-10-13

Completion date

2026-12-31

Last updated

2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer, Invasive Cancer

Brief summary

This is a prospective, multi-center clinical study of Multi-Cancer Early Detection (MCED) testing in cancer patients and healthy volunteers. The purpose of this study is to establish MCED platform through the analysis of whole genome sequencing of circulating DNA. The study will enroll 4,000 subjects as defined by eligibility criteria at up to 10 clinical institutions in South Korea.

Detailed description

AIMA is analysing whole genome sequencing data of circulating tumor DNA, combined through machine learning technique, to develop MCED platform to detect early stage cancer. The purpose of this prospective, multi-center, observational study is to validate an MCED platform for the early detection of cancers. The investigators will collect blood samples from subjects who are diagnosed as invasive cancers before treatment or from healthy volunteers.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Aged 19 years or older * Subjects who have been diagnosed with stages 1 to 4 of solid tumor or healthy volunteers who have scheduled a cancer screening examination * Subjects who have agreed to provide clinical information and blood samples * Subjects who have agreed for the storage and secondary use of residual blood samples for research * Subjects who have understood the study and are able to provide a written informed consent

Exclusion criteria

* Subjects who are not appropriate for the study because of intellectual disabilities or severe mental disorders * Subjects with a history of HIV, HTLV, or Syphilis infection * Subjects with primary site unknown cancer or synchronous or metachronous double primary cancers * Subjects who have diagnosed with any other malignant tumor within the past 5 years (except for cured non-melanoma skin cancer, in situ cancer, or thyroid cancer)

Design outcomes

Primary

Measure	Time frame
Diagnosis of invasive cancer, assessed by positive predictive value and negative predictive value	36 months
Accuracy of prediction for the origin of cancer, assessed by concordance rate	36 months

Countries

South Korea

Contacts

Primary ContactJoohyuk Sohn

oncosohn@yuhs.ac+82-2-2228-8135

Outcome results